
The approval is supported by data from the phase 3 LITESPARK-011 trial.
Chicago-Morbidity and hospital stay after standard post-chemotherapyretroperitoneal lymph node dissection (RPLND) decreased in testis cancerpatients undergoing the procedure over a 10-year period, even no changesoccurred in surgical technique. Researchers from Indiana University Schoolof Medicine suggest that this outcome probably reflects changes in care.




